 |
answer text |
<p>In the event that the UK leaves the EU with a negotiated deal, the Department’s
assessment is that during the Implementation Period agreed with the EU, market access
to medicines and medical devices won’t change for industry or the NHS.</p><p>We are
working closely with partners across the health and care system and industry, to take
all appropriate steps to prepare for leaving the European Union. Our robust plans
and multi layered approach should help ensure the supply of medicines and medical
products, including insulin, remains uninterrupted if we leave without a deal.</p><p>On
26 June, we wrote to suppliers of medicines to the United Kingdom from or via the
EU or European Economic Area setting out our continuing multi-layered approach to
support continuity of supply of medicines and medical products.</p><p>For commercial
reasons, the Government will not be releasing details of contingency plans for individual
medicines. We continue to work with individual suppliers directly to assure ourselves
of their contingency plans. However, as an example of the preparations being taken
by industry, insulin manufacturer Novo Nordisk recently publicly stated that they
have 18 weeks' worth of supplies in the UK and had secured alternative ferry capacity
to renew supplies.</p><p>Further details can be found at the following link:</p><p><a
href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans"
target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p>
</p>
|
|
